Novo Nordisk A/S (ADR) (NYSE:NVO)

CAPS Rating: 5 out of 5

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.

Results 1 - 20 of 105 : 1 2 3 4 5 6 Next »

Recs

1
Member Avatar TMFLomax (90.38) Submitted: 12/4/2015 2:21:51 PM : Outperform Start Price: $56.96 NVO Score: -6.82

Impressive CEO who seems to appreciate the big-picture view of running a responsible pharmaceutical business in an environment in which many such companies are under fire for their practices. He runs the business with ESG factors in mind. Diabetes is a huge and increasing market, of course, but the responsible business element here, which is aligned with the higher purpose of what pharmaceutical companies should be most concerned with (making people well and treating their diseases) is the most compelling element to me.

Recs

0
Member Avatar jorbas (< 20) Submitted: 11/7/2015 5:04:42 AM : Outperform Start Price: $52.83 NVO Score: -2.53

tresiba will become the next levemir

Recs

0
Member Avatar Bobmoll36 (38.67) Submitted: 10/19/2015 1:11:30 PM : Outperform Start Price: $55.80 NVO Score: -7.94

Just following the fool. Drug companies appear to be unchecked and profits go up. I need these profits to pay for my drugs which just go up and up and every 5-10 years go down but by then a new one has come out. what a business!

Recs

0
Member Avatar CMFmdriver78 (< 20) Submitted: 9/21/2015 9:02:25 AM : Outperform Start Price: $50.49 NVO Score: -5.99

Type 2 Diabetes could affect 50-percent of world population by 2050 and NVO has targeted that market since 1923.

Recs

0
Member Avatar ERojo (< 20) Submitted: 9/16/2015 9:22:50 AM : Outperform Start Price: $55.94 NVO Score: -10.00

diabetes and obesity

Recs

0
Member Avatar mrgekko (47.10) Submitted: 8/24/2015 2:39:35 PM : Outperform Start Price: $53.19 NVO Score: -9.22

world class diabetes drugs and pipeline, huge global issue that will take years if not decades to reverse - China especially an issue - huge percent of population with diabetes

Recs

1
Member Avatar SchrodingersCat (< 20) Submitted: 6/29/2015 4:33:02 PM : Underperform Start Price: $55.01 NVO Score: +4.79

Novo Nordisk is due a massive correction along with the Danish political and monetary system.

Recs

0
Member Avatar gideonstrauss (48.76) Submitted: 5/4/2015 11:21:52 AM : Outperform Start Price: $56.82 NVO Score: -5.66

Novo Nordisk is using human science research to understand the emotional experience of diabetes patients and as a result is focusing its long-term strategy on motivating patients towards well-being. Deep understanding of the experience of one's customers is an enduring competitive advantage. (More: http://www.redassociates.com/cases/novo-nordisk/)

Recs

0
Member Avatar andrewtraylor (33.36) Submitted: 4/28/2015 7:10:18 PM : Outperform Start Price: $55.57 NVO Score: -4.32

Outstanding margins & ROE- you get what you pay for.

Recs

0
Member Avatar MikeCinKC (32.24) Submitted: 11/24/2014 10:15:53 AM : Outperform Start Price: $44.06 NVO Score: +16.25

Great pipeline.

Recs

0
Member Avatar statman33 (< 20) Submitted: 9/10/2014 11:10:30 PM : Outperform Start Price: $45.85 NVO Score: +8.54

Diabetes treatment is key to health in the future. Well run.

Recs

0
Member Avatar WesKirk (62.11) Submitted: 7/2/2014 5:18:35 AM : Outperform Start Price: $45.76 NVO Score: +7.69

Basically, diabetes care and management has begun to significantly improve, as the cure for diabetes is closer and closer in sight. Unlike some of the other competitition, this company has medicine that doesn't require massive FDA testing and issues during such, and I feel its going to be a force to be reckoned with down the line.

Recs

0
Member Avatar knockripper (31.70) Submitted: 6/23/2014 2:14:14 PM : Outperform Start Price: $45.39 NVO Score: +7.90

biotech is future!!!!!!

Recs

0
Member Avatar invbrow (< 20) Submitted: 6/14/2014 10:59:12 AM : Outperform Start Price: $45.04 NVO Score: +7.78

Favorable FDA Ruling on Victoza for obesity indication in September will bring new Rx's for an existing product.

Recs

0
Member Avatar aymo0003 (< 20) Submitted: 5/1/2014 11:00:51 PM : Outperform Start Price: $43.83 NVO Score: +7.80

1. Market leader in a growing industry
2. Excellent management
3. Fundamentals
4. Profitable growth
5. Diabetes

Recs

0
Member Avatar afewgoodstocks11 (20.93) Submitted: 3/22/2014 12:02:00 AM : Outperform Start Price: $31.88 NVO Score: +27.03

The stock NVO has paid out a dividend of $0.61245. NVO seems to pay dividend once a year. Caps has the wrong div on the stock page, even though i got the alert.

Div. (Yield) $0.61 (1.389%)
Current Yield . . . . . . . 1.89%

Recs

0
Member Avatar danyariv (< 20) Submitted: 1/11/2014 5:13:07 PM : Outperform Start Price: $37.86 NVO Score: +22.11

diabetes is an epidemy, daily new people are discovered

Recs

0
Member Avatar Sagetology (58.07) Submitted: 12/27/2013 11:36:41 PM : Outperform Start Price: $35.79 NVO Score: +29.29

Competitors are facing patent expiry. The world is experiencing a growing need for diabetes treatment.

Recs

1
Member Avatar Stockllama10 (56.58) Submitted: 12/24/2013 6:33:07 PM : Outperform Start Price: $35.18 NVO Score: +31.27

1.) The P/E, P/B, P/CF, and P/S might not be pretty, but compare that to the overall industry and the concerns vanish. Especially with a fair value picked from $210 by Seeking Alpha and $222 by Morningstar.

2.) A solid moat with a large portfolio of successful drugs, although Tresiba might not be released to the U.S until past 2017, giving Sanofi some time to chip away. But...

3.) A Morningstar Stewardship Grade of "Exemplary". They were also ranked among the most innovative companies by Forbes magazine. As it is stated in Walter Issacson's biography of Steve Jobs: "The mark of an innovative company is not only that it comes up with new ideas first. It also knows how to leapfrog when it finds itself behind." If only one company has the right leadership in this, it's Novo. Not convinced they're good enough? Try a 94% approval rating of the CEO on Glassdoor.

Recs

0
Member Avatar oldfart65 (36.96) Submitted: 10/21/2013 11:45:07 AM : Outperform Start Price: $34.05 NVO Score: +30.35

Danish company which dominates the diabetes mkt (49% of mkt). 371m people have diabetes. Just announced stk buyback program. Worldwide exposure. Significant growth and high returns. 1.8% dividend. ADR but followed in US

Results 1 - 20 of 105 : 1 2 3 4 5 6 Next »

Featured Broker Partners